JLE

Hépato-Gastro & Oncologie Digestive

MENU

Cancers œsogastriques : les sept erreurs à ne pas (plus) faire Volume 26, supplément 2, Novembre 2019

  • [1] Integrated genomic characterization of oesophageal carcinoma. Nature 2017 ; 541(7636) : 169-75.
  • [2] TNCD. SNFGE.org. Société savante médicale française d’hépato-gastroentérologie et d’oncologie digestive [Internet]. [cité 7 juill 2019]. Disponible sur : https://www.snfge.org/tncd.
  • [3] Zaanan A, Bouché O, Benhaim L, et al. Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis 2018 ; 50 (8) : 768-79.
  • [4] Di Fiore A., Lecleire S., Gangloff A. Impact of nutritional parameter variations during definitive chemoradiotherapy in locally advanced oesophageal cancer. Dig Liver Dis. 2014;46:270-275. 3
  • [5] Spaander M.C.W., Baron T.H., Siersema P.D. Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2016;48:939-948. 10
  • [6] Yu F.J., Shih H.Y., Wu C.Y. Enteral nutrition and quality of life in patients undergoing chemoradiotherapy for esophageal carcinoma: A comparison of nasogastric tube, esophageal stent, and ostomy tube feeding. Gastrointest Endosc. 2018;88:21-31. 1
  • [7] Gomez-Martín C., Lopez-Rios F., Aparicio J. A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond. Cancer Lett. 2014;351:30-40. 1
  • [8] Cunningham D., Allum W.H., Stenning S.P. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20. 1
  • [9] Ychou M., Boige V., Pignon J.-P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715-1721. 13
  • [10] Al-Batran S-E, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2/3 trial. Lancet 2019 ; 393 (10184) : 1948-57.
  • [11] Santé publique France. Estimations nationales de l’incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018. Tumeurs solides/2019/Maladies chroniques et traumatismes/Rapports et synthèses/Publications et outils/Accueil [Internet]. [cité 7 juill 2019]. Disponible sur : https ://www.santepubliquefrance.fr/docs/estimations-nationales-de-l-incidence-et-de-la-mortalite-par-cancer-en-france-metropolitaine-entre-1990-et-2018-hemopathies-malignes-etude-a-pa.
  • [12] GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: A meta-analysis. JAMA 2010 ; 303(17) : 1729-37.
  • [13] Macdonald J.S., Smalley S.R., Benedetti J. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-730. 10
  • [14] Brenner H., Arndt V., Stürmer T., Stegmaier C., Ziegler H., Dhom G. Individual and joint contribution of family history and Helicobacter pylori infection to the risk of gastric carcinoma. Cancer. 2000;88:274-279. 2
  • [15] Haute Autorité de Santé. Infection par Helicobacter pylori chez l’adulte : la HAS précise les actes de diagnostic et les modalités de traitement [Internet]. [cité 7 juill 2019]. Disponible sur : https ://www.has-sante.fr/jcms/c_2775406/fr/infection-par-helicobacter-pylori-chez-l-adulte-la-has-precise-les-actes-de-diagnostic-et-les-modalites-de-traitement.
  • [16] Fan F, Wang Z, Li B, Zhang H. Effects of eradicating Helicobacter pylori on metachronous gastric cancer prevention: A systematic review and meta-analysis. J Eval Clin Pract. 2019 May 29. doi : 10.1111/jep.13179.[Epub ahead of print].
  • [17] Messager M., Lefevre J.H., Pichot-Delahaye V. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: A multicenter comparative study. Ann Surg. 2011;254:684-693. 5
  • [18] Rüschoff J., Dietel M., Baretton G. HER2 diagnostics in gastric cancer – guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457:299-307. 3
  • [19] Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010 ; 376 (9742) : 687-97.
  • [20] Tabernero J., Hoff P.M., Shen L. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): Final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19:1372-1384. 10
  • [21] Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): An international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol 2017 ; 18 (5) : 640-53.
  • [22] Satoh T., Xu R.-H., Chung H.C. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. J Clin Oncol. 2014;32:2039-2049. 19
  • [23] Kohlruss M, Grosser B, Krenauer M, et al. Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas : role of Epstein-Barr virus infection and high- and low-microsatellite instability. J Pathol Clin Res 2019 Jun 17. doi : 10.1002/cjp2.137.[Epub ahead of print].
  • [24] Smyth EC, Wotherspoon A, Peckitt C, et al. Mismatch Repair Deficiency, Microsatellite Instability, and Survival. JAMA Oncol [Internet]. sept 2017 [cité 7 juill 2019] ; 3 (9). Disponible sur : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824280/.
  • [25] Choi YY, Kim H, Yang H-K, et al. Clinical impact of microsatellite instability in patients with stage II and III gastric cancer: Results from the CLASSIC trial. J Clin Oncol 2017 ; 35 (15 Suppl.) : 4022-4022.
  • [26] Giampieri R., Maccaroni E., Mandolesi A. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. Gastric Cancer. 2017;20:156-163. 1
  • [27] Maccaroni E., Bracci R., Giampieri R. Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal? Oncotarget. 2015;6:38737-38748. 36
  • [28] Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015 ; 372 (26) : 2509-20.
  • [29] Le DT, Durham JN, Smith KN, et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017 ; 357 (6349) : 409-13.
  • [30] Janjigian Y.Y., Bendell J., Calvo E. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol. 2018;36:2836-2844. 28